Page last updated: 2024-09-03

blonanserin and raclopride

blonanserin has been researched along with raclopride in 2 studies

Compound Research Comparison

Studies
(blonanserin)
Trials
(blonanserin)
Recent Studies (post-2010)
(blonanserin)
Studies
(raclopride)
Trials
(raclopride)
Recent Studies (post-2010) (raclopride)
12121931,802132419

Protein Interaction Comparison

ProteinTaxonomyblonanserin (IC50)raclopride (IC50)
D(2) dopamine receptorHomo sapiens (human)0.052
D(2) dopamine receptorMus musculus (house mouse)0.032
D(2) dopamine receptorRattus norvegicus (Norway rat)0.0279

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Arakawa, R; Fukuta, H; Honjo, K; Ishihara, K; Kumita, S; Nakamura, H; Okubo, Y; Okumura, M; Tateno, A1
Kakuyama, H; Kim, W; Nishibe, H; Okubo, Y; Sakayori, T; Tateno, A; Yamamoto, M1

Trials

1 trial(s) available for blonanserin and raclopride

ArticleYear
Striatal Dopamine D2 Receptor Occupancy Induced by Daily Application of Blonanserin Transdermal Patches: Phase II Study in Japanese Patients With Schizophrenia.
    The international journal of neuropsychopharmacology, 2021, 02-15, Volume: 24, Issue:2

    Topics: Adult; Antipsychotic Agents; Corpus Striatum; Female; Humans; Japan; Male; Middle Aged; Piperazines; Piperidines; Positron-Emission Tomography; Raclopride; Receptors, Dopamine D2; Schizophrenia; Transdermal Patch; Young Adult

2021

Other Studies

1 other study(ies) available for blonanserin and raclopride

ArticleYear
Striatal and extrastriatal dopamine D2 receptor occupancy by a novel antipsychotic, blonanserin: a PET study with [11C]raclopride and [11C]FLB 457 in schizophrenia.
    Journal of clinical psychopharmacology, 2013, Volume: 33, Issue:2

    Topics: Adult; Antipsychotic Agents; Blood-Brain Barrier; Brain; Case-Control Studies; Corpus Striatum; Dopamine Antagonists; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Piperazines; Piperidines; Positron-Emission Tomography; Pyrrolidines; Raclopride; Receptors, Dopamine D2; Salicylamides; Schizophrenia; Tissue Distribution; Young Adult

2013